64Cu-LLP2A for Imaging Hematologic Malignancies

Recruiting Early Phase 1 Interventional Study
Multiple Myeloma Low-Grade Lymphoma Follicular Lymphoma Marginal Zone Lymphoma Lymphoplasmacytic Lymphoma Small Lymphocytic Lymphoma Chronic Lymphocytic Leukemia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Diagnostic
Participants needed
42 (estimated)
Sponsor
Washington University School of Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-gr…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria Healthy Volunteer: * Adult 18 years of age or older * Able to give informed consent. * Able to comprehend and willing to follow instructions for study procedures as called for by the protocol * Capable of lying still and supine within the PET/CT scanner for up to 75 minutes. * No…
Contacts

Farrokh Dehdashti, M.D.

314-362-1474

dehdashtif@wustl.edu

CONTACT

Jennifer Frye, CNMT, CCRC

314-747-1604

fryej@wustl.edu

CONTACT